{
    "clinical_study": {
        "@rank": "152909", 
        "arm_group": [
            {
                "arm_group_label": "Aripiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)"
            }, 
            {
                "arm_group_label": "risperidone or paliperidone", 
                "arm_group_type": "Active Comparator", 
                "description": "Stay on risperidone (RIS) or paliperidone (PALI)"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial designed to investigate the effect of switching to aripiprazole from risperidone\n      or paliperidone on reverse prolactin level, and consequently improve sexual dysfunction in\n      adult patients with schizophrenia spectrum disorders and bipolar spectrum disorders."
        }, 
        "brief_title": "A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Sexual Dysfunction", 
            "Hyperprolactinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperprolactinemia", 
                "Schizophrenia", 
                "Sexual Dysfunctions, Psychological"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: 12-55 years (male), 12-40 (female)\n\n          2. Diagnosis: Schizophrenia spectrum disorders & bipolar spectrum disorders (only Korea)\n             by DSM-IV-TR\n\n          3. Receiving RIS or PALI with stable dose for > 1 month by their physician;\n\n          4. Prolactin level  Adult: > 20 ng/ml (male), 25 ng/ml (female) Child/Adolescent: > 20\n             ng/ml (male, female)\n\n          5. Children and adolescents (age: 12~17 years) having more than one sexual system\n             dysfunction measured by 5 of the 48 UKU items (galactorrhoea, gynecomastia and\n             erectile dysfunction for male, galactorrhea, amenorrhoea/oligomenorrhoea, and dry\n             vagina for female) or Adults (age: 18~55 years) who are considered to have\n             sexual/reproductive dysfunction if they had either a total score of 19 or higher; a\n             score of 5 or higher on one question; or a score of 4 or higher on 3 questions.\n\n          6. Subjects who have consented to participate by signing an informed consent form.\n\n             -\n\n        Exclusion Criteria:\n\n          1. Medical disorder or psychiatric comorbidity or condition known to affect prolactin,\n             sex hormone balance or bone metabolism (i.e., unstable medical disease, Cushing's\n             disease, chronic renal failure, thyroid dysfunction, eating disorder)\n\n          2. History of hematological and/or solid malignancies\n\n          3. Physical or functional obstruction to food intake or impaired digestive/absorptive\n             function\n\n          4. Known hypersensitivity to any study medication (risperidone, paliperidone, and\n             aripiprazole)\n\n          5. Insulin requiring diabetes mellitus or poorly controlled diabetes mellitus (HbA1c >\n             9% or change of antidiabetics treatment within the 12weeks prior to screening)\n\n          6. Uncontrolled hypertension (SBP/DBP 140/90 mmHg), congestive heart failure (NYHA class\n             III or IV), other significant cardiovascular illness (myocardial infarction, unstable\n             angina, cardiac arrhythmia etc.)\n\n          7. Baseline QTc interval of > 450 msec\n\n          8. Hepatic and/or renal dysfunction\n\n        1) Bilirubin level  \u2265 1.5  upper normal limits 2) AST/ALT  \u2265  3  UNL or 3) Serum\n        creatinine  \u2265 1.5 9. Any patient hospitalized for acute exacerbation of their condition\n        within 2 months of randomization 10. Recent (within the past 1 month) or planned treatment\n        with prohibited medications in the protocol\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742390", 
            "org_study_id": "ARI_IIT_01/02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aripiprazole", 
                "description": "Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)", 
                "intervention_name": "Aripiprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "risperidone or paliperidone", 
                "intervention_name": "risperidone or paliperidone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Risperidone", 
                "9-hydroxy-risperidone", 
                "Aripiprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "schizophrenia", 
            "risperidone", 
            "paliperidone", 
            "aripiprazole"
        ], 
        "lastchanged_date": "March 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "si.tian-mei@163.cm", 
                    "last_name": "Tianmei Si, MD.", 
                    "phone": "8610-82801948"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100191"
                    }, 
                    "name": "Institute of mental health, Peking University"
                }, 
                "investigator": {
                    "last_name": "Tianmei Si, MD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xueyi Wang, Professor", 
                    "phone": "0311-85917290"
                }, 
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China", 
                        "state": "Hebei", 
                        "zip": "050000"
                    }, 
                    "name": "The first hospital of Hebei Province University"
                }, 
                "investigator": {
                    "last_name": "Xueyi Wang", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "si.tian-mei@163.com", 
            "last_name": "Tianmei Si, MD.", 
            "phone": "861082801948"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in severity of sexual/reproductive system dysfunction at 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742390"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Si Tianmei", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of absence of sexual/reproductive system dysfunction on the UKU side effect rating scale or ASEX", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Si Tianmei", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}